Check 35,000+ stocks against 26 valuation models and 37 quality factors

Bangkok Genomics Innovation Pcl (BKGI) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Bangkok Genomics Innovation Pcl THB 1.51, price THB 2.36, upside -36.0%, quality 43 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? No
Add to watchlist

Healthcare · TH

BG Thin data Sep 24, 2026

Bangkok Genomics Innovation Pcl

BKGI · BK

Weakest SetupStrongly overvalued and low quality.

!Fair value 1.51 THB · Strongly overvalued (−36%)

!Quality 43/100

!Expensive Growth (revenue 5y +23.2 %/yr)

✓Solidly profitable · 15.1% net margin (TTM)

!negative free cash flow

·2.12% dividend yield

✓Ranks above peers (8/12)

!Moderate moat 60/100

!Evidence only low, so the estimate is less certain

26 models, one by oneBear 1.21 THB to bull 1.81 THB Growth analysisrevenue history, year by year Quality 43/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Bangkok Genomics Innovation Pcl for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

30‑month range 1.10 THB – 5.11 THB · fair‑value band 1.21 THB – 1.81 THB · the 2.36 THB price screens above the 1.51 THB fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Bangkok Genomics Innovation Pcl in your weekly email

Every Wednesday you see whether Bangkok Genomics Innovation Pcl is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Bangkok Genomics Innovation Public Company Limited provides medical analysis services in Thailand.

Bangkok Genomics Innovation Public Company Limited provides medical analysis services in Thailand. The company offers screening for fetal chromosomal abnormalities using non-invasive prenatal testing under the NIFTY brand, preimplantation chromosomal abnormality and thalassemia carrier gene screening, infectious disease group analysis, and monkeypox virus analysis. It also provides other screening tests, such as cancer-related gene screening to predict the risk of inherited cancer, monitor treatment, select drugs that are appropriate for one's genetics, and provide treatment and disease prevention. In addition, the company offers genetic analysis using whole exome sequencing, a technology that can detect gene abnormalities that cause diseases; individual genetic decoding, which involves detailed genetic sequencing to analyze genetic information and identify aspects such as ethnicity or ancestry, optimal exercise profiles, metabolic capabilities, and the risk of genetic diseases; newborn screening; and health check-ups for various needs. Further, it supports research services in both medical and other fields, offers DNA and RNA sequencing, metabolomics and proteomics services, and medical products comprising genetic sequencers; NIPT, PGT-A, hereditary cancer screening, and precision oncology solutions; real-time PCR that includes beta thalassemia genotyping and human papillomavirus genotyping kits; and cell-free DNA storage tubes. The company serves government sectors such as medical schools and health centers, as well as private sectors such as clinics, hospitals, private medical laboratories, research institutes, and universities. Bangkok Genomics Innovation Public Company Limited was founded in 2017 and is headquartered in Bangkok, Thailand.

Stock analysis

Bangkok Genomics Innovation Pcl (BKGI) currently trades at 2.36 THB, while our model-based Fair Value estimate is 1.51 THB, implying the stock looks roughly 56.3% overvalued today.

Valuation

Bull case: the Growth Earnings group reads highest at a median of 2.07 THB per share, and 1 of the 17 models we run sit above the 2.36 THB price.

Bear case: the Asset-Based group reads lowest at 0.6200 THB, and 16 of the 17 models stay below the price. Evidence for this calculation is low.

Scenario range: 1.21 THB (bear) to 1.81 THB (bull), the price of 2.36 THB sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Bangkok Genomics Innovation Pcl reported revenue of 380M THB in FY2025 versus 379M THB in FY2021, a compound +0.0%/yr. Reported net income was 45.3M THB in FY2025, compounding −19.1%/yr from FY2021.

Key figures

Market cap 1.4B THB (≈ $42.5M) · P/E ratio 29.5 · P/S ratio 3.53 · EPS (TTM) 0.0800 THB · Dividend yield 2.1% · Net margin 11.9% · Return on equity 12.1% · Return on assets (EBIT) 20.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 44 out of 100 (low confidence).

What moves the price

The share trades about 3% below its 52-week high and 99% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −36%, BKGI screens richer than that median.

Fair Value models

Bear 1.21 THB Fair Value 1.51 THB Bull 1.81 THB

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.0220 THB per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

Residual Income 0.7600 THB 0.8200 THB 0.9100 THB 76

Owner Earnings 1.15 THB 2.07 THB 3.91 THB 70

EPV 0.9500 THB 1.04 THB 1.12 THB 70

All 17 models by family

DCF Models

Owner Earnings 1.15 THB 2.07 THB 3.91 THB 70

Earnings-Based

Graham-Dodd 0.5100 THB 3.50 THB 4.91 THB 63

Lynch FV 1.03 THB 1.47 THB 1.91 THB 61

PEG = 1.0 1.03 THB 1.47 THB 1.91 THB 57

EPV 0.9500 THB 1.04 THB 1.12 THB 70

Dividend Discount

Gordon GGM 0.4100 THB 0.8200 THB 1.24 THB 67

DDM Multi-Stage 0.4100 THB 0.7100 THB 0.8600 THB 67

Multiples

P/E Multiple 1.25 THB 1.66 THB 2.08 THB 63

P/S Multiple 0.9600 THB 1.28 THB 1.61 THB 58

P/B Multiple 0.9600 THB 1.28 THB 1.61 THB 55

EV/EBIT 1.27 THB 1.57 THB 1.87 THB 63

EV/EBITDA 1.49 THB 1.86 THB 2.23 THB 64

EV/Revenue 1.01 THB 1.29 THB 1.56 THB 52

Asset-Based

NCAV (Graham) 0.4600 THB 0.6200 THB 0.9200 THB 51

Economic Profit

Residual Income 0.7600 THB 0.8200 THB 0.9100 THB 76

ROIC Compounder 0.9700 THB 1.21 THB 1.42 THB 70

Growth Earnings

Growth-Adj P/E 1.45 THB 2.07 THB 2.69 THB 67

Open the full fair value analysis →

Notify me when BKGI reaches fair value

Put BKGI on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 43/100

Of which business quality 43 · Market factors (momentum, volatility) 75

Profitability 43

Margins and returns on capital today

Quality Growth 35

Are margins and returns improving?

Cashflow 0

Earnings quality: real cash, not paper profit

Fin. Strength 100

Balance sheet, leverage, solvency risk

Investment 19

Disciplined investing over empire-building

Low Volatility 38

Calm price path (market factor)

Momentum 88

Price trend over the last 3–12 months (market factor)

52W Momentum 96

Distance to the 52-week high (market factor)

Net Issuance 53

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 62/100

The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Revenue growth 1 year

+12.4%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+7.6%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+23.2%

Start year 2020 (pandemic)

Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+27.1%

’18

’19

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years), in THB ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in THB: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.

−2.8%

Earnings growth per share plus dividend.

Earnings per share, growth per year−4.9%

Dividend (yield on the price)2.1%

Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.10% → 11%

⚠ Revenue per share shrinking 4.4%/yr over ~5Y (margins intact) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.

BKGI screens 56% overvalued. Compare with Thermo Fisher Scientific Inc →

Compare Bangkok Genomics Innovation Pcl with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 143 stocks

Beats the industry median on 8/12 measures

Overall it ranks above its industry peers.

Valuation

Quality Score 43 · Below median

Fair Value upside −36% · Below median

Profitability

Return on equity (TTM) 12% · Top 25%

Return on assets 7% · Top 25%

Net margin (TTM) 15% · Top 25%

Operating margin (TTM) 24% · Top 25%

Growth and dividend

Revenue growth 94% · Top 25%

Dividend yield (TTM) 2.1% · Above median

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/E (TTM) 29.5× · Cheaper than median

P/B 2.57× · Pricier than median

P/S (TTM) 3.13× · Pricier than median

EV/EBITDA 12.8× · Cheaper than median

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)0 · sector 0

FUTURE (revenue growth)100 · sector 25

PAST (return on equity)48 · sector 8

HEALTH (low debt)0 · sector 95

DIVIDEND (yield)42 · sector 30

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Thermo Fisher Scientific Inc TMO	$665.30	$682.58	+3%
Danaher Corporation DHR	$221.09	$207.76	−6%
WuXi AppTec Co 2359	HK$207.60	HK$228.36	+10%
Lonza Group LONN	CHF 570.00	CHF 151.69	−73%
IDEXX Laboratories, Inc IDXX	$522.02	$495.84	−5%
Agilent Technologies, Inc A	$165.32	$63.90	−61%
Waters Corporation WAT	$425.74	$106.31	−75%
IQVIA Holdings IQV	$270.09	$295.80	+10%
Illumina, Inc ILMN	$255.38	$280.92	+10%
Mettler-Toledo International Inc MTD	$1,491	$635.75	−57%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Bangkok Genomics Innovation Pcl · Fair Value
1.51 THB −56%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/BKGI" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Bangkok Genomics Innovation Pcl · Fair Value</span><br><b style="font-size:20px">1.51 THB</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−56%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Bangkok Genomics Innovation Pcl Fair Value". https://www.fairvalue-calculator.com/stock/BKGI

Frequently asked questions

Is Bangkok Genomics Innovation Pcl (BKGI) overvalued or undervalued?

As of Sep 24, 2026, our model estimates a fair value of 1.51 THB versus a price of 2.36 THB, about −36% upside (overvalued).

What is the fair value of BKGI?

Our model-based fair value for Bangkok Genomics Innovation Pcl is 1.51 THB (as of Sep 24, 2026), built from audited fundamentals. The current price: 2.36 THB.

What is the quality score of BKGI?

Bangkok Genomics Innovation Pcl has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Bangkok Genomics Innovation Pcl (BKGI)?

Our model-based price target is the fair value of 1.51 THB (as of Sep 24, 2026) from 17 valuation models. Cautious scenario 1.21 THB, optimistic scenario 1.81 THB. It is a calculation from audited fundamentals, not an analyst target.

What is the Bangkok Genomics Innovation Pcl stock forecast for 2026?

Our models put fair value at 1.51 THB, about −36% upside versus a price of 2.36 THB (overvalued). Cautious scenario 1.21 THB, optimistic scenario 1.81 THB. The calculation is refreshed regularly with new filings.

What is the revenue of Bangkok Genomics Innovation Pcl (BKGI)?

Bangkok Genomics Innovation Pcl reported trailing-twelve-month revenue of about 453M THB (latest available figure, as of Sep 24, 2026).

Does Bangkok Genomics Innovation Pcl pay a dividend?

Bangkok Genomics Innovation Pcl currently shows a dividend yield of about 2.12% relative to its recent price (as of Sep 24, 2026).

What is the intrinsic value of Bangkok Genomics Innovation Pcl (BKGI)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bangkok Genomics Innovation Pcl it is 1.51 THB per share (as of Sep 24, 2026), against a price of 2.36 THB. It is the blended result of 17 valuation models (cash flow, earnings, asset, dividend).

Is Bangkok Genomics Innovation Pcl stock overvalued or undervalued in 2026?

As of Sep 24, 2026, BKGI trades above its calculated fair value: price 2.36 THB, fair value 1.51 THB, a gap of about −36% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of BKGI?

No. The price is what the market pays today (2.36 THB); the fair value is what the company's own numbers justify (1.51 THB). For Bangkok Genomics Innovation Pcl the two are 0.8500 THB per share apart. That gap is exactly why we show both numbers side by side.

How much is Bangkok Genomics Innovation Pcl worth?

The market values Bangkok Genomics Innovation Pcl at about 1.4B THB (market capitalisation, as of Sep 24, 2026). Per share that is 2.36 THB; our models calculate a fair value of 1.51 THB per share.

What do the bullish and bearish scenarios say about BKGI?

Our models span a range for Bangkok Genomics Innovation Pcl: cautious scenario 1.21 THB, base 1.51 THB, optimistic 1.81 THB per share (as of Sep 24, 2026, price 2.36 THB). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of BKGI?

Bangkok Genomics Innovation Pcl trades at a price-to-earnings ratio of 29.5 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 1.51 THB is built from several models across several years. Other multiples: P/B 2.6, P/S 3.1, EV/EBITDA 12.8.

How solid is the balance sheet of Bangkok Genomics Innovation Pcl (BKGI)?

Balance-sheet figures for Bangkok Genomics Innovation Pcl (as of Sep 24, 2026): return on equity 12.1%. They feed the Quality Score of 43/100, which measures business quality independently of the share price.

How far is BKGI from its 52-week high?

Bangkok Genomics Innovation Pcl trades at 2.36 THB, about 3% below its 52-week high of 2.44 THB and 99% above the low of 1.19 THB (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 1.51 THB is for.

Which stocks are comparable to Bangkok Genomics Innovation Pcl?

From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Bangkok Genomics Innovation Pcl stock attractive at the current price?

The data as of Sep 24, 2026: price 2.36 THB, calculated fair value 1.51 THB (−36%), Quality Score 43/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of BKGI calculated?

We run Bangkok Genomics Innovation Pcl through 17 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1.51 THB, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 13.0 % above its aggregate fair value. Bangkok Genomics Innovation Pcl itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Bangkok Genomics Innovation Pcl (BKGI)?

The closing price on Sep 24, 2026 was 2.36 THB. Our model-based fair value is 1.51 THB, about −36% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Bangkok Genomics Innovation Pcl right now?

The price sits above even our optimistic bull case (1.81 THB). The favourable scenario is already priced in. Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Bangkok Genomics Innovation Pcl

How large is the market capitalisation of Bangkok Genomics Innovation Pcl (BKGI)?

The market capitalisation of Bangkok Genomics Innovation Pcl is 1.4B THB (≈ $42.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Bangkok Genomics Innovation Pcl (BKGI)?

The price-to-sales ratio of Bangkok Genomics Innovation Pcl is 3.53 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Bangkok Genomics Innovation Pcl (BKGI)?

Earnings per share at Bangkok Genomics Innovation Pcl are 0.0800 THB (price ÷ EPS = P/E 29.5). Earnings per share over the last twelve months: total profit spread across every single share.

What is the dividend yield of Bangkok Genomics Innovation Pcl (BKGI)?

The dividend yield of Bangkok Genomics Innovation Pcl is 2.1% (payout 62.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of Bangkok Genomics Innovation Pcl (BKGI)?

The net margin of Bangkok Genomics Innovation Pcl is 11.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Bangkok Genomics Innovation Pcl (BKGI)?

The return on equity (ROE) of Bangkok Genomics Innovation Pcl is 12.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Bangkok Genomics Innovation Pcl (BKGI)?

On an EBIT basis the return on assets of Bangkok Genomics Innovation Pcl is 20.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Bangkok Genomics Innovation Pcl (BKGI)?

The operating margin of Bangkok Genomics Innovation Pcl is 23.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Bangkok Genomics Innovation Pcl (BKGI)?

Revenue at Bangkok Genomics Innovation Pcl is growing +93.8% versus a year earlier (3y avg +7.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Bangkok Genomics Innovation Pcl (BKGI)?

Earnings per share at Bangkok Genomics Innovation Pcl are growing +285% versus a year earlier. How much earnings per share grew versus a year earlier.

How much free cash flow does Bangkok Genomics Innovation Pcl (BKGI) generate?

The free cash flow of Bangkok Genomics Innovation Pcl is −124M THB (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

How much net cash does Bangkok Genomics Innovation Pcl (BKGI) hold?

Bangkok Genomics Innovation Pcl holds more cash than debt, 184M THB net (fiscal year 2025). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch Bangkok Genomics Innovation Pcl in the live analysis

One click puts Bangkok Genomics Innovation Pcl on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.